Evidence map›Paper›PMID 39591119›Full record

ArticleVaccines2024

Immunogenicity and Safety of the Recombinant Adjuvanted Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia and Multiple Myeloma.

Panagiotis T Diamantopoulos, Christina-Nefeli Kontandreopoulou, Christos Stafylidis, Dimitra Vlachopoulou, Stavroula Smilakou, Iraklis Patsialos, Stavroula Syriopoulou, Alexandros Gkikas, Eleftherios N Athanasopoulos, Anastasios Vogiatzakis and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Panagiotis T DiamantopoulosHematology Unit, First Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece.ORCID 0000-0003-2692-5944
Christina-Nefeli KontandreopoulouHematology Unit, First Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece.
Christos StafylidisHematology Unit, First Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece.ORCID 0000-0003-3918-4401
Dimitra VlachopoulouHematology Unit, First Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece.
Stavroula SmilakouDepartment of Microbiology, Laikon General Hospital, 11527 Athens, Greece.
Iraklis PatsialosHematology Unit, First Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece.
Stavroula SyriopoulouHematology Unit, First Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece.
Alexandros GkikasDepartment of Microbiology, Laikon General Hospital, 11527 Athens, Greece.
Eleftherios N AthanasopoulosLaboratory of Biochemistry, Department of Chemistry, University of Patras, 26504 Patras, Greece.
Anastasios VogiatzakisDepartment of Microbiology, Laikon General Hospital, 11527 Athens, Greece.ORCID 0009-0003-1465-4451
Eleni PanousiDepartment of Microbiology, Laikon General Hospital, 11527 Athens, Greece.
Georgios KyriakakisHematology Unit, First Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece.
Amalia AnastasopoulouHematology Unit, First Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece.
Marina MantzouraniHematology Unit, First Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece.
Vassiliki LabropoulouSchool of Health Sciences, Faculty of Medicine, Hematology Division, University of Patras, 26504 Patras, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesPatients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are susceptible to viral infections, including varicella-zoster virus (VZV) reactivation due to both disease-related and treatment-induced immunosuppression. The recombinant adjuvanted herpes zoster vaccine (RZV) has shown high efficacy in immunocompetent adults, but immunogenicity data in CLL and MM patients are limited. This study evaluates the immunogenicity and safety of RZV in this population.

methodsPatients with CLL and MM vaccinated with RZV (administered in two doses at least one month apart) were included in the study. Pre- and post-vaccination anti-VZV IgM and IgG antibody levels were measured to assess immunogenicity, and adverse events (AEs) were captured for safety evaluation.

resultsSeventy-eight patients received both vaccine doses, and 71 had post-vaccination samples. Most of the patients were IgM seronegative and IgG seropositive before vaccination. Pre-vaccination IgG levels were higher in CLL patients compared to MM patients (

conclusionsRZV demonstrated strong immunogenicity and acceptable safety in CLL and MM patients, significantly boosting IgG levels, even in actively treated or heavily pretreated patients.

Indexed as

chronic lymphocytic leukemiaimmunogenicitymultiple myelomarecombinant adjuvanted herpes zoster vaccine (RZV)safetyvaricella-zoster virus (VZV)

Identifiers

PMID39591119
PMCPMC11598597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.